BioCurex, Inc.(fka BOCX)

[renos4]

This statement by the company is quite specific.

The improvements resulting from this work have magnified the measured differences in serum values for RECAF between normal and cancer patients. This large difference between cancers and normal patients not only allows the detection of smaller tumors, (as recently shown for breast cancers where we can now detect 90% of early stages I and II); but it is also a requirement for a "yes/no" rapid test similar to a pregnancy test that could be used directly in the doctors' offices."

It indicates that the colorometric test is better than the radioactive one. It also indicates that on a limited sample basis they are having favorable results on early detection. They admit that more work needs to be done. They are trying hard to get a company to buy the rights and finish the development of both early detection and general discovery for the cororometric test. I think you are being a little too negative Kag because a lab may buy into this and start a fire under this stock. (my opinion only)
renos